Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NEOG vs AHCO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AHCO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–5 Matrix Metrics)
AHCO Overall Winner
6-Pillar Tally: NEOG 3 – 3 AHCO
Matrix Metrics: NEOG 5 – 4 AHCO
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NEOG carries a Unified Composite Score of 45.2/100 (HOLD) at $10.55 (35.2x Forward P/E, -0.8% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin).
- Technical & Structure Timing Caution: NEOG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0); meanwhile AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NEOG vs AHCO
NEOG
Neogen Corp
$10.55
-2.76% 1D
Market Cap
$2.4B
TTM Revenue
$884M
Forward P/E
35.2x
Beta / 30D Vol
1.35β · 41% Vol
Unified Composite Score
45.2
HOLD
Tech 30.0
Fund 47.0
Flow 56.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
AHCO
Head-to-Head Winner
AdaptHealth Corp. Common Stock
$7.20
-0.69% 1D
Market Cap
$989.8M
TTM Revenue
$3.44B
Forward P/E
7.8x
Beta / 30D Vol
0.17β · 67% Vol
Unified Composite Score
45.2
HOLD
Tech 29.0
Fund 46.0
Flow 54.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (NEOG 3 – 3 AHCO)
1. Valuation Multiples
AHCO
Forward P/E
35.2x
7.8x
Trailing P/E
16.0x
7.8x
PEG Ratio
0.66x
N/M
EV / Revenue
3.4x
0.9x
2. Growth & Scale
AHCO
Revenue Growth (YoY)
+6.5%
+10.9%
Earnings Growth (YoY)
-85.6%
+6.7%
TTM Revenue (USD)
$884M
$3.44B
Market Cap
$2.4B
$989.8M
3. Profitability & Quality
NEOG
Gross Margin
47.4%
18.2%
Operating Margin
-0.8%
3.8%
Net Profit Margin
-6.3%
-11.8%
Return on Equity (ROE)
-2.7%
-28.4%
4. Balance Sheet & Cash Flow
NEOG
Cash Generation (TTM)
$50M
$82M
Cash Flow Margin
5.6%
2.4%
Net Cash / Leverage
$602M Net Debt (0.37x D/E)
$1.97B Net Debt (1.67x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AHCO
Options Structure Phase
CONSOLIDATION
SURGE
Current IV / %ile
46.0% (25th %ile)
66.9% (12th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
NEOG
OpEx & R&D Intensity
48.2% of Rev ($426M)
14.4% of Rev ($495M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NEOG (5) vs AHCO (4)| Institutional Metric | NEOG | AHCO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.4B | $989.8M | NEOG | |
| Trailing P/E Ratio | 16.0x | 7.8x | AHCO | |
| Forward P/E Ratio | 35.2x | 7.8x | AHCO | |
| Revenue Growth (YoY) | +6.5% | +10.9% | AHCO | |
| Operating Margin (TTM) | -0.8% | 3.8% | AHCO | |
| Net Profit Margin | -6.3% | -11.8% | NEOG | |
| Return on Equity (ROE) | -2.7% | -28.4% | NEOG | |
| 52-Week Range Position | 58% ($5–$14) | 24% ($5–$13) | NEOG | |
| Beta / 30D Volatility | 1.35β · 41% Vol | 0.17β · 67% Vol | NEOG | |
| Unified Institutional Score | 45.2 / 100 (HOLD) | 45.2 / 100 (HOLD) | Tie | |
| Trailing 12M Revenue (USD) | $884M | $3.44B | Scale | |
| Gross Profit Margin (TTM) | 47.4% | 18.2% | Quality | |
| PEG Ratio & EV / Revenue | 0.66x PEG · 3.4x EV/Rev | N/M PEG · 0.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $50M ($602M Net Debt (0.37x D/E)) | $82M ($1.97B Net Debt (1.67x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AHCO +28.63 pp
3M Horizon
AHCO +36.94 pp
6M Horizon
NEOG +49.64 pp
1Y Horizon
NEOG +110.29 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NEOG Revenue | AHCO Revenue | NEOG Op. Margin | AHCO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $410M | $530M | 16.4% | 5.5% | NEOG |
| FY2020 | $420M | $1.06B | 16.1% | 6.8% | NEOG |
| FY2021 | $470M | $2.45B | 15.8% | 9.2% | NEOG |
| FY2022 | $530M | $2.97B | 11.1% | 6.4% | NEOG |
| FY2023 | $820M | $3.20B | 4.6% | -18.7% | NEOG |
| FY2024 | $920M | $3.26B | 6.3% | 8.1% | AHCO |
| FY2025 | $890M | $3.24B | -118.6% | 2.8% | AHCO |
| FY2026 | $870M | N/A | -2.5% | N/A | NEOG |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NEOG
CONSOLIDATION
Current IV
46.0%
IV Percentile
25th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NEOG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AHCO
SURGE
Current IV
66.9%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NEOG Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
48.2% of Rev ($426M)
90D Engineering Disclosures
0 Published
AHCO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
14.4% of Rev ($495M)
90D Engineering Disclosures
0 Published
Investor FAQ NEOG vs AHCO Key Questions & Quantitative Answers
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NEOG carries a Unified Composite Score of 45.2/100 (HOLD) at $10.55 (35.2x Forward P/E, -0.8% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin). Technical & Structure Timing Caution: NEOG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0); meanwhile AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AHCO leads the Growth & Scale pillar: NEOG posts +6.5% YoY revenue growth and -85.6% YoY earnings growth on $884M TTM revenue (47.4% gross margin, -0.8% operating margin), compared with AHCO at +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), NEOG cumulative revenue shifted +112.2% while AHCO shifted +511.3%. In operating R&D and SG&A reinvestment, NEOG deploys 48.2% of Rev ($426M) (0 90-day corporate R&D disclosures) versus 14.4% of Rev ($495M) (0 disclosures) for AHCO.
AHCO screens cheaper on headline valuation multiples. NEOG trades at 35.2x Forward P/E, 16.0x Trailing P/E, 0.66x PEG, and 3.4x EV/Revenue (5.6% FCF margin), whereas AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEOG (-2.7% ROE) versus AHCO (-28.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NEOG carries 46.0% implied volatility (25th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.35β · 41% Vol realized risk). By comparison, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AHCO vs NEOG · Reverse Pair
NEOG vs MMSI
· Sector Peer
NEOG vs ICUI
· Sector Peer
NEOG vs EXPO
· Sector Peer
AHCO vs OPCH
· Sector Peer
AHCO vs ADUS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem